Gary Patou - Dec 13, 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Sherry Aulin, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Dec 13, 2023
Transactions value $
-$741,409
Form type
4
Date filed
12/15/2023, 05:38 PM
Previous filing
Jun 2, 2023
Next filing
Jun 5, 2024
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $62.8K +6.38K +27.06% $9.85 30K Dec 13, 2023 Direct F1, F2
transaction XENE Common Shares Tax liability -$50.7K -1.28K -4.27% $39.68 28.7K Dec 13, 2023 Direct F1, F3
transaction XENE Common Shares Sale -$199K -5.1K -17.79% $38.94 23.6K Dec 13, 2023 Direct F1, F4
transaction XENE Common Shares Options Exercise $28.4K +2.88K +12.22% $9.85 26.5K Dec 13, 2023 Direct F1, F2
transaction XENE Common Shares Tax liability -$22.9K -577 -2.18% $39.68 25.9K Dec 13, 2023 Direct F1, F3
transaction XENE Common Shares Sale -$90K -2.3K -8.9% $39.10 23.6K Dec 13, 2023 Direct F1, F5
transaction XENE Common Shares Options Exercise $46.3K +5.14K +21.82% $9.00 28.7K Dec 13, 2023 Direct F1
transaction XENE Common Shares Tax liability -$46.3K -1.17K -4.06% $39.68 27.6K Dec 13, 2023 Direct F1, F3
transaction XENE Common Shares Sale -$158K -3.98K -14.44% $39.84 23.6K Dec 13, 2023 Direct F1
transaction XENE Common Shares Sale -$312K -7.6K -60.78% $41.05 4.9K Dec 13, 2023 See Note F1, F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -6.38K -100% $0.00* 0 Dec 13, 2023 Common Shares 6.38K $9.85 Direct F2
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -2.8K -100% $0.00* 0 Dec 13, 2023 Common Shares 2.8K $9.85 Direct F2
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -5.14K -100% $0.00* 0 Dec 13, 2023 Common Shares 5.14K $9.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.
F2 The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F3 Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.